GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Aidea Pharmaceutical Co Ltd (SHSE:688488) » Definitions » Forward PE Ratio

Jiangsu Aidea Pharmaceutical Co (SHSE:688488) Forward PE Ratio : 0.00 (As of May. 12, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Jiangsu Aidea Pharmaceutical Co Forward PE Ratio?

Jiangsu Aidea Pharmaceutical Co's Forward PE Ratio for today is 0.00.

Jiangsu Aidea Pharmaceutical Co's PE Ratio without NRI for today is 0.00.

Jiangsu Aidea Pharmaceutical Co's PE Ratio (TTM) for today is 0.00.


Jiangsu Aidea Pharmaceutical Co Forward PE Ratio Historical Data

The historical data trend for Jiangsu Aidea Pharmaceutical Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Aidea Pharmaceutical Co Forward PE Ratio Chart

Jiangsu Aidea Pharmaceutical Co Annual Data
Trend
Forward PE Ratio

Jiangsu Aidea Pharmaceutical Co Quarterly Data
Forward PE Ratio

Competitive Comparison of Jiangsu Aidea Pharmaceutical Co's Forward PE Ratio

For the Biotechnology subindustry, Jiangsu Aidea Pharmaceutical Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Aidea Pharmaceutical Co's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jiangsu Aidea Pharmaceutical Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Jiangsu Aidea Pharmaceutical Co's Forward PE Ratio falls into.


;
;

Jiangsu Aidea Pharmaceutical Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Jiangsu Aidea Pharmaceutical Co  (SHSE:688488) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Jiangsu Aidea Pharmaceutical Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Jiangsu Aidea Pharmaceutical Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Aidea Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 2 Liuzhuang Road, Hanjiang District, Jiangsu Province, Yangzhou, CHN, 225008
Jiangsu Aidea Pharmaceutical Co Ltd produces and sells human-derived protein products, and also develops some generic drug businesses and distributes Abbott's HIV diagnostic equipment and reagents. The company focuses on development of new chemical entities of anti-tumor, anti-virus and cardiovascular areas, among which two NCE drugs for the treatment of Cancer and AIDS have been approved.
Executives
Wang Jun Directors, senior managers
Fu He Liang Director, core technical staff
Zhang Jie Directors, senior managers
Yuan Yu Core technical personnel
Su Gu Fang Core technical personnel
Zhang Ji Bing Core technical personnel
Wang Guang Rong Directors, senior managers
Yu Ke Directors, senior managers

Jiangsu Aidea Pharmaceutical Co Headlines

No Headlines